Share Market Newspaper

Chronic Hepatitis Delta Virus (HDV) Infection Market Size & Share, Epidemiology and Competitive Analysis Report 2032 | Companies – MYR Pharmaceuticals, Eiger BioPharmaceuticals

 Breaking News
  • No posts were found

Chronic Hepatitis Delta Virus (HDV) Infection Market Size & Share, Epidemiology and Competitive Analysis Report 2032 | Companies – MYR Pharmaceuticals, Eiger BioPharmaceuticals

May 18
19:28 2023
Chronic Hepatitis Delta Virus (HDV) Infection Market Size & Share, Epidemiology and Competitive Analysis Report 2032 | Companies - MYR Pharmaceuticals, Eiger BioPharmaceuticals
Chronic Hepatitis Delta Virus (HDV) Infection Market
DelveInsight’s “Chronic Hepatitis Delta Virus (HDV) Infection – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chronic Hepatitis Delta Virus (HDV) Infection, historical and forecasted epidemiology as well as the Chronic Hepatitis Delta Virus (HDV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Chronic Hepatitis Delta Virus (HDV) Infection Market Report 2032” delivers an in-depth understanding of the Chronic Hepatitis Delta Virus (HDV) Infection, historical and forecasted epidemiology as well as the Chronic Hepatitis Delta Virus (HDV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hepatitis delta, also known as hepatitis D or HDV is a liver infection caused by the hepatitis delta virus that results in the most severe form of viral hepatitis known to humans. However, only those already infected with hepatitis B can acquire hepatitis delta, as it is dependent on the hepatitis B virus to reproduce.

The HDV infection is of two types: superinfection and co-infection. Super infections occur when a person with chronic hepatitis B becomes infected with hepatitis delta. These types of infections are more common and have a 70‒90% chance of resulting in a chronic infection of both hepatitis B and delta. Co-infections occur when a person gets infected with hepatitis B and delta at the same time, and have a <5% chance of resulting in chronic infections.

Request for sample pages: https://www.delveinsight.com/sample-request/chronic-hepatitis-delta-virus-infection-market

Chronic Hepatitis Delta Virus Infection Disease Understanding and Treatment Algorithm

HDVC is percutaneously transmitted through contact with infected blood or blood products. Vertical transmission is possible, but rare. Chronic liver disease, which may occur with hepatitis D, often has minimal symptoms. At times there may be mild flare-ups with jaundice, nausea, fatigue, and weight loss.

There are at least eight different types of hepatitis delta called “genotypes,” which are associated with distinct disease progression. In general, a more severe condition occurs in genotype 1 and 3, and milder in genotype 2. Generally, a single genotype tends to dominate in an infected person, but multiple genotypes can occur in those at high risk of repeated exposure to the virus.

The diagnosis will require two tests, namely the hepatitis delta antibody (Anti-HDV total) and the hepatitis delta RNA (HDV RNA). The HDV antibody total test is the first step, as people who have recovered from or are currently infected with hepatitis delta will have antibodies. If the HDV antibody total test is positive, it should be followed by the HDV RNA test to confirm an active infection. If this test is negative, a current infection is unlikely.

Chronic Hepatitis Delta Virus (HDV) Infection Epidemiology  

It is estimated that globally, approximately 5% of people with chronic HBV infection are co-infected with HDV, resulting in a total of 15‒20 million persons infected with HDV worldwide. The high-prevalence areas include Africa, Asia, Pacific Islands, Middle East, Eastern Europe, South America, and Greenland. Superinfections have a 70‒90% chance of resulting in a chronic infection of both hepatitis B and delta. Coinfections have a <5% chance of resulting in chronic infections.

The Chronic Hepatitis Delta Virus (HDV) Infection epidemiology division provide insights about historical and current Chronic Hepatitis Delta Virus (HDV) Infection patient pool and forecasted trend for every seven major countries.

Key Findings

According to the study by Gaeta et al., titled “Chronic Hepatitis D: A Vanishing Disease? An Italian Multicenter Study,” the prevalence of anti-HDV among HBV carriers with liver disease decreases from 25% in 1983 to 14% in 1992 in Italy and from 15.1% to 7.1% in Spain.

Download sample pages: https://www.delveinsight.com/sample-request/chronic-hepatitis-delta-virus-infection-market

Chronic Hepatitis Delta Virus (HDV) Infection Drug Chapters

The current clinical pipeline of chronic HDV infection is weak. The key players that are working toward the development of therapies for chronic HDV infection are MYR Pharmaceuticals and Eiger BioPharmaceuticals.

Drug chapter segment of the Chronic Hepatitis Delta Virus (HDV) Infection market report encloses the detailed analysis of Chronic Hepatitis Delta Virus (HDV) Infection marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

Chronic Hepatitis Delta Virus (HDV) Infection Market Outlook

Currently, no treatment has been approved by the US FDA for chronic HDV infection. As HDV requires HBV for its replication, it can be prevented by the use of hepatitis B vaccine.

The treatment recommendations to date are based on the experience with IFN-based therapy. Current guidelines of the American Association for the Study of Liver Diseases (AASLD), Asian Pacific Association for the Study of the Liver (APASL), and the European Association for the Study of the Liver (EASL) recommend peg-IFN-α for 12 months in patients with compensated liver disease with consideration of nucleoside and nucleotide analogue therapy with ongoing HBV DNA replication, and referral to specialized centers for experimental therapies given limited efficacy of pegylated interferon-α (peg-IFN-α).

IFN-α, peg-IFN-α, and combination therapy with nucleoside or nucleotide analogues have been studied in chronic HDV infection, but therapy with IFN is largely limited to patients who are non-cirrhotic.

Novel treatment options have been evaluated recently, and four areas of interest include drugs that target entry, assembly and release of viral particles in addition to treatment that activates the immune host response. The use of HBV nucleoside and nucleotide analogue as monotherpay or in combination with IFN-α therapy has been explored in chronic HDV infected patients.

The Chronic Hepatitis Delta Virus (HDV) Infection market outlook of the report helps to build the detailed comprehension of the historical, current, and forecasted Chronic Hepatitis Delta Virus (HDV) Infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Chronic Hepatitis Delta Virus (HDV) Infection market in 7MM is expected to change in the study period 2019-2032.

Request for sample pages of the report: https://www.delveinsight.com/sample-request/chronic-hepatitis-delta-virus-infection-market

Table of contents

1 Key Insight

2 Executive Summary of Catheter-Related Bloodstream Infection (CRBSI)

3 Catheter-Related Bloodstream Infection (CRBSI) Market Overview at a Glance

4 Disease Background and Overview: Catheter-Related Bloodstream Infection (CRBSI)

5 Case Reports

6 Catheter-Related Bloodstream Infection (CRBSI) Epidemiology and Patient Population

7 United States Epidemiology

8 EU5 Epidemiology

9 Japan Epidemiology

10 Current Catheter-Related Bloodstream Infection (CRBSI) Treatment and Medical Practices

11 Unmet needs

12 Catheter-Related Bloodstream Infection (CRBSI) Marketed Drugs

13 Catheter-Related Bloodstream Infection (CRBSI) Emerging Drugs

14 Catheter-Related Bloodstream Infection (CRBSI) 7MM Market Analysis

15 United States

16 EU-5 countries: Market Outlook

17 Japan Market Outlook

18 Catheter-Related Bloodstream Infection (CRBSI) Market Drivers

19 Catheter-Related Bloodstream Infection (CRBSI) Market Barriers

20 SWOT Analysis

21 Reimbursement and market access

22 Appendix

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/